Type Whole antibody Target CD30 CAS Number 640735-09-7 | Source Human ATC code none ChemSpider none | |
Iratumumab is a human monoclonal antibody used in the treatment of oncological diseases such as relapsed refractory CD30-positive lymphoma including Hodgkin's disease.
This drug was developed by Medarex, which was later acquired by Bristol-Myers Squibb.
The FDA granted orphan drug designation for Hodgkin's lymphoma in 2004. In 2009, development was suspended with no explanation given.
References
Iratumumab Wikipedia(Text) CC BY-SA